One Step Vending Corp. is a holding company utilizing an acquisition-based strategy and cooperative agreements with established businesses to promote sustainable growth and rapid increases in market share. Following the acquisition of a controlling interest in Corporate Refreshment Services (CRS) earlier this year, the company is currently focused on becoming a leader in the micro market industry, with key business sectors including food and refreshment services, self-checkout systems and mobile vending.

“CRS has a solid track record of profitability and a sophisticated sales and marketing know-how regarding small and medium businesses,” Brian Duke, president of One Step, stated in a news release. “We expect that this combination will help both companies to grow and we look forward to working with their team and providing them with the broad resources and capabilities that we have to offer.”

Through its micro market platforms, One Step, through CRS, provides unstaffed, self-checkout food store solutions that integrate seamlessly into office spaces. The company’s machines provide a healthier alternative to traditional vending machines by offering fresh snack and meal options that have been shown to improve employee health and promote increased productivity. By accepting a collection of payment methods and utilizing web-based reporting and monitoring systems, One Step is able to maximize its returns from each installed micro market unit.

The potential marketability of One Step’s healthy approach to vending machines is immense. According to a study by Automatic Merchandiser, micro markets represent the fastest growing segment in the vending industry, and this success can be at least partially attributed to the continued shift in consumer preference toward healthier snacking options. In a 2013 study by Hartman Group, approximately 57 percent of Americans rated healthy snack options as important, further demonstrating the significant upside of micro market technology.

According to industry data, micro markets attract about 18 percent more visits than traditional vending machines, and as many as 72 percent of resulting purchases are made with cashless payment methods. Look for One Step to capitalize on these statistics by leveraging its interest in CRS, effectively promoting sustainable growth in the months to come. For prospective shareholders, the company’s commitment to its acquisition-based growth strategy, as well as its established presence in the fastest growing segment in the vending industry, should provide a platform for considerable market growth moving forward.

For more information, visit www.onestepvend.com

Medical cannabis and cannabinoid-based therapies are gaining wider acceptance around the United States. More than 20 states and the District of Columbia have legalized the drug and, between 2009 and 2014, IBISWorld estimates that the medical cannabis industry grew significantly to reach $2 billion in revenue. Despite this industry boom and the pioneers that emerged within it, there has been a shortage of companies conducting legitimate research and development and/or with the right amount of scientific backing and funding needed to compete in the industry.

GrowBLOX Sciences, a biopharmaceutical research and development company, stands out from the pack with its advanced technologies in plant biology and cultivation. Led by an impressive scientific team that includes big data experts, the company has turned its attention to creating safe, standardized pharmaceutical-grade cannabis-based therapies that target an assortment of medical conditions. The company is focused on bringing relief to patients in communities across the country by combining ground-breaking technology and industry processes with its “big” data-driven clinical research and development loop ability. Moreover, through its Puerto Rico subsidiary, GrowBLOX Sciences is developing and dispensing its suite of cultivation and growing chambers worldwide.

With its novel approach to using big data to produce lower-risk clinical trial candidates, GrowBLOX is highlighting its strong long-term potential. With over 180 cannabis-related human trials registered with the National Institute of Health (NIH) and more on the way, the company has established a brilliant starting point with close to a thousand potential combinations within the cannabinoid-related therapy space.

In the short term, the company intends to earn revenue from selling certified raw materials through dispensaries. These near-term plans were set in May when the company announced the formation of GrowBLOX Sciences Puerto Rico, a subsidiary that will legally grow cannabis raw materials that will be sold solely to its parent company for dispersion in the U.S. and other countries where the drug is legal.

The company’s operations – cultivation, post-processing and manufacturing – create a model platform to execute these visions. On the cultivation side, its TissueBLOX, GrowBLOX and CureBLOX platforms facilitate the efficient growing of cannabis, while its ExtractionLab produces proprietary blends for distribution as pharmaceuticals, nutraceuticals and cosmeceuticals. Given its distinctive business model, long-term potential in pharmaceuticals and short-term potential in raw material sales, GrowBLOX Sciences is a company worth a closer look.

For more information, visit the company’s website at www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

Location Based Technologies, Inc. (OTC: LBAS) designs and builds dedicated GPS products and services that are both affordable and easy to use. The company’s extensive product lines – which are marketed under the PocketFinder and LBT brands – feature submersible waterproof, virtually indestructible GPS devices that provide customers with easy to manage, customizable location information that can be accessed from almost anywhere and at any time.

In recent months, the company has refocused its resources in an effort to realize sustainable market growth. In particular, LBAS signed contracts with both a world-class distributor and key strategic retail outlets in order to expand its sales in both the United States and Mexico. The company recently announced the shipment of initial orders related to its agreement with a leading distributor in Mexico. These orders are expected to generate significant device and service revenue throughout the remainder of 2015.

Additionally, following the introduction of its 3G vehicle tracker devices, LBAS recently launched a new auto dealership reseller program in North America focused on increasing installations at the time of new and pre-owned vehicle sales. The company expects this program to significantly strengthen its commercial sales and augment its ongoing business sales.

“Each of our key initiatives for 2015 provides dynamic growth opportunities that will carry us to our ultimate achievement of profitability,” Dr. David M. Morse, chief executive officer of LBAS, stated in a news release.

In its fiscal quarter ending May 31, LBAS leveraged the marketability of its product lines to promote strong financial growth. The company’s net revenue for the quarter was just under $552,000, representing a 21 percent year-over-year increase. This performance was attributable to increased sales for the period, including a 28 percent increase in paid monthly users, as compared to the previous year.

LBAS is in a favorable position to build on its recent financial performance in the months to come. Look for the company to maximize its presence in both domestic and international markets in the future through continued focus on expanding upon its existing sales agreements and product lines.

For more information, visit www.pocketfinder.com or www.locationbasedtech.com

In the second quarter of 2015, ENGlobal Corp. (NASDAQ: ENG) recorded its sixth straight quarter of profitable results. In large part, these results were attributable to the consistent performance of the company’s engineering and construction segment, which accounted for over 61 percent of ENGlobal’s total revenue for the period. Despite the recent drop in oil and gas prices, which continue to hover near six-year lows, the segment’s performance was a mild improvement over the second quarter of 2014, further highlighting the effectiveness of the company’s current strategy aimed at expanding its market share and locating new clients and business opportunities.

“ENGlobal’s response to the current energy marketplace has been to increase our efforts in developing new business,” William Coskey, P.E., chairman and chief executive officer of ENGlobal, stated in a news release. “While we are excited about several new opportunities and client relationships that this internal process has produced, it also appears to be a great time to consider strategic acquisitions.”

In addition to its profitable results in the second quarter, ENGlobal continues to maintain a favorable balance sheet, which should give the company an opportunity to capitalize on current market conditions through an aggressive pursuit of new client relationships and potential strategic acquisitions. As of its latest filings, ENGlobal reported a healthy cash balance and working capital of $25.4 million with no borrowings under its current credit facility.

Over the past three decades, ENGlobal has built a significant presence in a collection of energy markets through its unique commitment to innovation and cost-effective automation. With services ranging from feasibility studies and conceptual design to turnkey project responsibility, the company has established itself as a mainstay among the country’s top engineering firms. For this reason, ENGlobal has been ranked by Engineering News Record magazine as a Top 500 engineering design firm for more than 10 years.

ENGlobal’s strong results from its engineering and construction segment were supplemented by the performance of its automation segment. Although total revenue for the segment declined from the results of the previous year, the company was able to increase the segment’s gross profit margin by 7.4 percent in order to help it maintain profitability for the quarter.

For prospective shareholders, the company’s profitable results despite current market conditions continue to highlight the immense value of its experienced management team. Moving forward, look for ENGlobal to continue capitalizing on the opportunities presented by the current condition of the energy marketplace in order to promote strong results for the future.

For more information, visit www.englobal.com

As the ongoing “Green Rush” continues to pick up momentum across the U.S., with more and more states inexorably on the road to either passing transformative medical marijuana legislation that is effectively the narrow end of the wedge, or blanket decriminalization, as is the case in Alaska, Colorado ($700 million in 2014), Oregon, Washington, and D.C., the smart money is increasingly focused on pick-and-shovel plays which provide the requisite equipment and services needed for the industry to thrive. Instead of trying to grow, sell or otherwise manufacture cannabis and cannabis based products themselves, a handful of sector players are banking on doing for this now $2.7 billion U.S. market what Halliburton (NYSE: HAL) does for the energy industry, capitalizing on the very legal and logistical difficulties that face sector core companies which are avoided by pursuing this proven strategy, and facilitating the underlying market dynamics via provision of ancillary technologies and services.

With Ohio announcing that it is the latest state to advance towards reform on cannabis prohibition, as Ohio Secretary of State, Jon A. Husted recently reported a constitutional amendment will go before voters this November that would do in Ohio what was done in Alaska and Oregon back in November, it seems clear that the sector’s moment is now unstoppable. Similar moves by Arizona, Hawaii, Maine, Massachusetts, Missouri, Nevada and California, where estimates by leading sector analysts ArcView currently place the initial market potential in this one state alone as topping out around $10 billion if full legalization is passed, are an unambiguous indicator to investors about the forward vector of this yet-nascent industry.

This is why companies like Fastfunds Financial (OTC: FFFC) are bullish about the potential for broad-spectrum “field service” strategy in the cannabis sector, secure in the knowledge that during any such Gold Rush, the companies who will realize the biggest returns are not the core operators, but the guys on the sidelines selling the picks and shovels. FFFC’s shotgun approach has the company pursuing cannabis financial services based on branded frequent buyer loyalty reward top-up cards, as well as cutting-edge antimicrobial sanitation systems for the grower market, and much-needed, high profit margin security services for the essentially all-cash retail market via its wholly-owned 420 Development Corporation subsidiary. In addition to these verticals, FFFC is focused on providing corporate development services and angel funding for sector start-ups not directly involved in growing or dispensing marijuana via its newly formed Cannabis Angel, Inc. subsidiary, which has already secured an agreement with a Minneapolis, Minnesota-based private equity fund to provide the requisite capital.

Fastfunds Financial has a significant advantage in the financial services end of the cannabis business, being already grounded as it is in providing such facilitation to the largely underserved Hispanic community via its majority-owned Financiera Moderna, Inc. subsidiary. Already off to a running start, with a branded series of transaction cards styled after cannabis sector legend Tommy Chong, FFFC’s recent signing of cannabis industry experts and advertising powerhouse, Casa Giallo, should take the company’s 49 percent stake in the Cannabis Merchant Financial Solutions, Inc. (CMFS) Green Card, Tommy Chong Green Card, and Tommy Chong Frequent Buyers Card, to the next level. This is a shrewd move by FFFC, tapping one of the sector’s most notable and well-connected marketing agencies, in order to ensure that their card options take center stage as the industry matures.

Casa Giallo, backed up by experts at Finnegan & Diba Law Firm, has been hugely successful with not only devising winning social media strategies, but comprehensive advertising, branding and marketing solutions as well, for such clients as Snoop Dogg, innovative medical marijuana ordering and delivery company Eaze, and numerous private farms in Northern California’s now world famous “Emerald Triangle” region, where most of the cannabis in the U.S. has been grown since the early 60’s. Tommy Chong and his licensed product lines have attracted a great deal of attention on name recognition alone and Fastfunds Financial, through CMFS, is dedicated to creating a national master distribution, sales and reseller network for its branded card products, something which should help substantially address many of the core transaction-related concerns that continue to hamper the industry.

Reloadable stored value cards, complete with rewards programs and frequent shopper bonuses, are a vital addition to the cannabis sector and will help address the security concerns held by many consumers and dispensaries in a very passive, yet effective fashion. However, FFFC is not content to stop there and the company is also eyeing the remaining chunk of this vertical through a 70 percent stake in diversified security, training and investigations outfit, Brawnstone Security, Inc., a fully functioning and currently operating security company based in Ohio. Evolving Brawnstone Security into a 21st century cannabis sector shield agency could be the most profitable vertical for FFFC too, with extant research indicating that operating margins could be double that of current billing levels for this business. Little surprise there really, as the demand from small, private dispensaries and farmers in particular shows no signs of slowing down. With more and more capital flooding into the industry on a daily basis, loss prevention demand and the need for security guards, systems, and law enforcement liaison work will only continue to increase.

A key operating agreement between FFFC and Sanidor Systems, a developer of proprietary, state-of-the-art formulas and advanced delivery systems for deodorizing, disinfecting and sanitizing personal, as well as industrial spaces, has put the company at the forefront of the commercial grower market facilitator space as well. The recent reception of registration approval for its general label in Washington and Wisconsin allows sales of the GroClean product – developed through the entity created by FFFC and Sanidor, known as Pure Grow Systems, LLC (in which Fastfunds Financial holds a 49 percent stake) – to commence, much to the delight of growers in those states, for whom such sanitizing and disinfecting technology is of inestimable importance. Today’s increasingly sophisticated grow ops have a huge demand for a variety of reasons when it comes to disinfecting and sanitizing their growing and processing facilities, and this milestone registration approval sets up the GroClean product nicely for rapid expansion into the much broader national medical and recreational grower market. GroClean is perfect for eliminating harmful bacteria such as salmonella and e-Coli, in addition to fungi, mildew, mold, viruses and pests like spider mites, showing exceptional results, even in hydroponic applications where moisture is a constant factor.

The company’s showcasing of the entire portfolio of antimicrobial sanitation products and systems available through Pure Grow Systems at the Hempfest on August 14th through the 16th in Seattle, Washington, is the sort of ideal marketing opportunity needed for FFFC to impress upon the broader industry just how attractive these highly cost-effective solutions are. Engineered from the ground up to deliver maximum kill ratios and plant coverage, these products containing 100 percent biodegradable active ingredients are powerful enough to guard against the major production pitfalls faced by all growers, and yet cheap enough to reasonably form the backbone of such efforts when it comes to planning a grow op budget. The distribution agreement signed back in July between Pure Grow Systems and developer of high-end electrostatic sprayers, Byoplanet, which gave Pure Grow Systems the ability to market delivery systems like the Byoplanet ES120 sprayer, goes a long ways towards cementing the grower market for FFFC. Using advanced induction charged technology to ensure that formulated products can cover 100 percent of target surfaces, the Byoplanet ES120 creates droplets with a tiny electrostatic charge that allows those droplets to reach hidden surfaces and penetrate deeper than is otherwise possible, making it a lifesaver for rapidly and effectively dispensing antimicrobial sanitation products.

Fastfunds Financial is well-positioned to drive mounting revenue generation for its shareholders in the coming years, as the cannabis sector goes from 74 percent growth between 2013 and 2014, to a projected 300 percent growth over the next four years, when ArcView estimates the sector could reach upwards of $10.8 billion annually.

To dig deeper, check out the FFFC website www.fastfundsfinancial.com

Let us hear your thoughts: Fastfunds Financial Corp. Message Board

RestorGenex Corp. (OTCQX: RESX) is a specialty biopharmaceutical company focused on the development of a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. The company’s lead product candidate, RES-529, is a novel PI3K/Akt/mTOR pathway inhibitor that has completed two phase I clinical trials for the treatment of age-related macular degeneration (AMD) and is in preclinical oncology development for the treatment of glioblastoma multiforme (GBM). RestorGenex has announced plans to initiate human clinical trials in GBM in 2016. Additionally, the company’s pipeline includes RES-440, a ‘soft’ anti-androgen compound for the treatment of acne vulgaris.

Through its ongoing development programs, RestorGenex is addressing a collection of underserved markets in the biopharmaceutical industry. According to industry data, the worldwide market for the treatment of GBM in 2013 was estimated at $1 billion, and that figure is expected to climb to $4.5 billion by 2020. Due to the modest effectiveness of currently available treatment options, this market performance could provide an opportunity for RestorGenex to achieve considerable financial growth upon commercialization of RES-529. The company’s innovative PI3K pathway inhibitor has also shown promise in a number of additional indications, which RestorGenex is currently evaluating for the purpose of creating safe and effective treatments.

“The scientific research and knowledge of RES-529 continues to expand, in particular for clinical oncology applications,” Stephen M. Simes, chief executive officer of RestorGenex, stated in a news release. “These new data help to validate our plans for future studies with RES-529, as well as suggest that its analogs could also be developed for oncology indications.”

Moving forward, RestorGenex will lean on the strength of its balance sheet as it progresses toward the commercialization of its promising development pipeline. As of June 30, 2015, the company reported cash and cash equivalents of approximately $16.5 million, which it expects to sufficiently fund its operations well into the second half of 2016. RestorGenex had no outstanding debt as of its latest financial filings.

For prospective shareholders, the potential marketability of RestorGenex’s development pipeline, particularly in oncology indications, could foreshadow an opportunity for the company to achieve considerable market growth in the future. Look for the company to continue benefitting from its favorable financial position as it advances its product candidates in the months to come.

For more information, visit www.restorgenex.com

Cherubim Interests is led by highly experienced directors and a notable management team proficient in specific disciplines of property management, construction and finance. The company has committed these specialties to sharpen the company’s focus on alternative construction and real estate development.

Primarily concentrated on the real estate development and controlled environment agriculture sectors, Cherubim Interests acquired an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Along these lines, the company plans on leveraging its wholly owned subsidiary, BudCube Cultivation Systems USA (“BCS”), to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.

Integrating real estate development and property management expertise, BCS has the ability to position itself anywhere in the world where the cultivation of cannabis is legal. This unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.

The legal marijuana market is the fastest-growing industry in the United States, and while it’s a fairly new industry, people are investing millions of dollars in key niches of the market, such as cannabis cultivation for medicinal purposes.

BCS’s current short-term opportunity is based solely on the legalization of Oregon Medical and Recreational Cannabis:

• Medical cannabis sales represents a market of $60 mm / year.
• Recreational cannabis sales represents a market of $550 – 600 mm / year.
• Demand for technology is strong.
• Demand is outpacing capacity in the short run.

Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim Interests is strategizing to use its licensed solution to fulfill the needs of first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product.

For more information visit http://CHIT.QualityStocks.net

Let us hear your thoughts: Cherubim Interests, Inc. Message Board

Avant Diagnostics, Inc. (OTC: AVDX) is a medical diagnostic technology company specializing in large panel biomarker screening. The company’s first test, OvaDx®, is being developed in conjunction with Arrayit Corporation (OTCQB: ARYC) as the market’s first large panel biomarker screening test for pre-symptomatic ovarian cancer. In preclinical research studies, OvaDx demonstrated high sensitivity and specificity for all types and stages of ovarian cancer – including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon reception of FDA 510(k) clearance for OvaDx, Avant intends to sell or license the innovative technology as a diagnostic test for women seeking greater wellness.

When commercialized, the market for Avant’s sophisticated microarray-based test is likely to be immense. According to statistics from the American Cancer Society, ovarian cancer ranks fifth in terms of cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. In 2015, it’s estimated that more than 21,200 women will receive a new diagnosis of ovarian cancer in the United States. For these women, early diagnosis can be pivotal to surviving the disease. If diagnosed in stage I, the five-year survivability rate of ovarian cancer is 90 percent, but that statistic falls to 70 percent if diagnosis occurs in stage II, further demonstrating the considerable market need for highly sensitive testing technology such as OvaDx.

Avant is led by a management team with decades of related industry experience. The company’s president and chief executive officer, Gregg Linn, has been with Avant since December 2012. Prior to serving in this position, Linn held similar positions at two firms specializing in providing strategic financial and business development advisory services to public and non-public businesses.

Moving forward, Avant will look to lean on its experienced management team in order to continue making progress toward the commercialization of its groundbreaking OvaDx diagnostic tool. In April, the company announced the engagement of DOCRO, Inc. to manage the preparation and submission of required data as necessary to obtain a 510(k) clearance for OvaDx as an aid in monitoring women diagnosed with ovarian cancer. For prospective shareholders, this progress could foreshadow an opportunity for considerable financial growth in the future.

For more information, visit www.avantdiagnostics.com

In an effort to elevate its cosmeceutical and nutraceutical product lines, Hemp, Inc. recently announced a full media partnership and public relations agreement with Freedom Leaf, Inc. (OTC: FRLF), a leading marijuana-related news, multimedia, entertainment, public relations and branding firm. Under the terms of this six-month campaign, Hemp, Inc. will receive a full-page advertisement in each of Freedom Leaf magazine’s monthly print editions, as well as its related digital and social media platforms. Following the commencement of this agreement on September 1, 2015, the company’s advertisements will appear in tens of thousands of copies throughout 32 states.

“We expect this national campaign launch to bolster existing marketing efforts and maximize profits,” Bruce Perlowin, chief executive officer of Hemp, Inc., stated in a news release. “The upcoming advertisements across Freedom Leaf’s platforms are designed to be a ‘call-to-action’ to join the industrial hemp revolution and fight misleading propaganda and long-standing misinformation on the hemp plant.”

This campaign, which is a continuation of the company’s aggressive marketing strategy for its existing line, will highlight Hemp, Inc.’s popular selection of hemp-infused products – including shampoos, conditioners, moisturizers, lip balms, skin treatment oils and candles. Additionally, these advertising efforts coincide with the impending launch of the company’s 70,000 square-foot decortication plant. When operational, this plant is expected to be the largest natural fiber manufacturing and processing facility in North America.

“I believe Hemp, Inc. is a true pioneer in the industrial hemp industry and I have high hopes about the direction in which Hemp, Inc. is moving,” stated Clifford J. Perry, chief executive officer of Freedom Leaf. “Their decortication plant in Spring Hope, North Carolina, is going to change the way we do business and help transition from non-sustainable synthetic solutions to more hemp-based clean, green solutions.”

Although banned in the U.S. under the Marijuana Tax Act of 1937, industrial hemp has been making a comeback in recent years. In 2014, Congress passed the federal Farm Bill, which allowed some states to cultivate the plant for research purposes. In March, North Dakota Gov. Jack Dalrymple took it one step further by signing a bill into law that laid the groundwork for a commercial hemp industry in the state. For Hemp, Inc., this rising sentiment around the country could provide a platform for sustainable financial growth in the future.

To date, Hemp, Inc. has completed the first stage of four toward preparing its manufacturing facility for operation. While the company awaits the legalization of industrial hemp in North Carolina, it plans to use the facility to process kenaf, a commercial fiber crop related to cotton. For prospective shareholders, the popularity of Hemp, Inc.’s existing product lines, as well as the near limitless market potential presented by its decortication plant, makes the company an intriguing investment opportunity moving forward. Look for Hemp, Inc. to continue capitalizing on its position in one of the country’s most rapidly expanding markets while awaiting additional regulatory reform.

For more information, visit www.hempinc.com

International Stem Cell Corporation is a biotechnology company utilizing a proprietary new stem cell technology known as parthenogenesis to significantly advance the field of regenerative medicine. The company’s innovative technology uses unfertilized human eggs to create human pluripotent stem cells (hpSC) that can be immune-matched to millions of people around the globe. These stem cells are unique in that they provide the best characteristics of each of the remaining classes of cells without the need for the creation or destruction of a viable embryo.

The company’s business strategy features three unique channels for revenue generation within the biotechnology industry – including its core stem cell technology and related intellectual property, which encompasses 220 patents, applications and licenses associated with the development and manufacture of pluripotent cells, as well as its therapeutic research projects and promising development pipeline.

Lifeline Skin Care, the company’s wholly-owned subsidiary, is an industry leader in effective anti-aging stem cell skin care. Since being established in 2010, Lifeline has served as a growing source of vital financial support to fund ISCO’s ongoing medical research. In 2014, Lifeline accounted for more than $7 million in total revenue, which was primarily allocated to the advancement of the company’s promising development pipeline.

UniStemCell is the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use. This cell bank gives the company a nearly inexhaustible source of stem cells that can be used to generate revenue in the medium term. As the company’s hpSC lines gain additional validation, they are expected to provide the company with royalty from sales of each successful hpSC-derived cellular therapeutic in the future.

In addition to the sale of its stem cells, ISCO is making noteworthy progress toward the continued advancement of its development pipeline. The company is currently engaged in pre-clinical development addressing a host of unmet medical needs. Parkinson’s disease, which affects an estimated one million people in the United States, represents ISCO’s leading development indication, with phase I/II clinical trials expected to begin in the coming months. Following the completion of initial studies, the company will seek out a suitable partner to assist with late-stage clinical development.

With its groundbreaking stem cell technology, ISCO is developing a significant presence within the expansive field of regenerative medicine. By successfully mitigating many of the limiting factors commonly associated with stem cell research – including auto-immune rejection and ethical debate surrounding the use of embryonic cells – the company is leveraging the marketability of its technology as a catalyst for continued growth.

Research indicates that the global regenerative medicine market is expected to grow at a CAGR of 12.2 percent through 2017, climbing to an estimated $24.7 billion by the end of the period. ISCO will look to capitalize on this market performance under the guidance of an executive management team with decades of experience in a collection of related scientific sectors.

For more information, visit www.internationalstemcell.com

Let us hear your thoughts: International Stem Cell Corp. Message Board